Original Research ARTICLE
Neuroprotective effects and mechanisms of Zhenlong Xingnao Capsule in in vivo and in vitro models of hypoxia
- 1Shandong University of Traditional Chinese Medicine, China
- 2Shandong Institutes for Food and Drug Control, China
- 3Xiangya Hospital, Central South University, China
Zhenlong Xingnao Capsule (ZXC) is a Tibetan medicine used to treat ischemic stroke. We aimed to clarify the role of ZXC in cerebral ischemia protection; reveal amino acid neurotransmitter changes in the frontal cortex after drug intervention; determine mRNA and protein expression changes in Bcl-2, Bax, caspase-3, P38, and nuclear factor (NF)-кB in the frontal cortex and changes in antioxidant indices in the brain; and elucidate the mechanisms underlying ZXC action.
Keywords: Zhenlong Xingnao Capsule, Middle cerebral artery occlusion model, Cerebral ischemia-reperfusion injury, Reactive Oxygen Species, BV-2 cell
Received: 14 Feb 2019;
Accepted: 26 Aug 2019.
Copyright: © 2019 Sun, Wei, Zhu, Liu, Xu, Wei, Fan, Sun, Zhao, Qiao, Wu, Hu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Dr. Peng Sun, Shandong University of Traditional Chinese Medicine, Jinan, China, firstname.lastname@example.org
Dr. Defu Hu, Shandong Institutes for Food and Drug Control, Jinan, 250101, Shandong Province, China, email@example.com
Dr. Yang Wang, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, China, firstname.lastname@example.org